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Abstract 
Background  Sleep-disordered breathing (SDB) is known to occur frequently in and may predict worsening progression of patients 
with congestive heart failure (CHF). SDB is also known to play an important role in the development of idiopathic pulmonary arterial hyper-
tension (PAH) via inducing endothelial dysfunction and vascular remodeling, a pathological process that can be significantly influenced by 
factors such as osteoprotegerin (OPG) and endothelial progenitor cells (EPCs). The objective of this study is to determine if CHF with SDB 
is associated with changes in OPG, EPCs, and PAH. Methods  EPCs were isolated, cultured, and quantified from CHF patients with SDB 
(n = 52), or without SDB (n = 68). OPG and N-terminal pro-brain natriuretic peptide (NT-proBNP) from each group was analyzed and cor-
related with EPCs and the mean pulmonary artery pressure (mPAP) measured by right heart catheterization. Results  A significant decrease 
in circulating EPCs (29.30 ± 9.01 vs. 45.17 ± 10.51 EPCs/× 200 field; P < 0.05) was found in CHF patients with SDB compared to those 
without SDB. Both OPG (789.83 ± 89.38 vs. 551.29 ± 42.12 pg/mL; P < 0.05) and NT-proBNP (5946.50 ± 1434.50 vs. 3028.60 ± 811.90 
ng/mL; P < 0.05) were also significantly elevated in SDB CHF patients who also had significantly elevated mPAP (50.2 ± 9.5 vs. 36.4 ± 4.1 
mm Hg; P < 0.05). EPC numbers correlated inversely with the episodes of apnea and hypopnea per hour (RDI, r = –0.45, P = 0.037) and 
blood level of OPG (r = –0.53, P = 0.011). Although NT-proBNP was also increased significantly in patients with SDB, it had no correlation 
with either EPCs or RDI. Conclusions  SDB due to hypoxemia from decompensated CHF is associated with (1) OPG elevation, (2) EPC 
depletion, and (3) mPAP elevation. The inverse relationship of circulating OPG with EPCs suggests a likely mechanism for hypoxemia and 
OPG in the development of pulmonary vascular dysfunction via depleting EPCs, thus worsening prognosis of CHF. 
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1  Introduction  
Approximately 5.1 million people in the United States 
have clinically manifested congestive heart failure (CHF), 
and the prevalence continues to rise.[1] The lifetime risk of 
developing HF is 20% for Americans ≥ 40 years of age. In 
the United States the CHF incidence has largely remained 
stable over the past several decades, with > 650,000 new 
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CHF cases diagnosed annually.[1,2] Recently, some studies  
have shown that approximately 50% of CHF patients have 
sleep-disordered breathing (SDB), which consists of ob-
structive sleep apnea (OSA) and Cheyne-Stokes respiration 
with central sleep apnea (CSA).[3,4] Some large studies have 
demonstrated that SDB is associated with adverse prognosis 
in CHF patients.[5,6] In addition, it is well known that SDB is 
associated with the development of pulmonary arterial hy-
pertension (PAH) because of nocturnal dyspnea. PAH also 
frequently develops during progression of CHF,[7,8] and un-
fortunately, the development of PAH in patients with CHF 
is associated with a worsening prognosis and greater mor-
tality.[1,2] 
In animal studies, pulmonary vascular remodeling is key 
to the pathogenesis of PAH.[5,6] Although the specific me-
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mechanisms of pulmonary vascular remodeling remain not 
completely understood, experimental studies have impli-
cated several molecules previously associated with idio-
pathic PAH that may play a central role. During chronic 
heart failure abnormal bone morphogenetic protein receptor 
type II (BMPR2) expression could secrete osteoprotegerin 
(OPG) from pulmonary artery endothelial cells.[9] OPG is a 
soluble member of the tumor necrosis factor receptor family, 
which regulates osteoclast differentiation.[9,10] The BMPR2- 
OPG pathway activation may also result in damage for 
some types of cells, such as endothelial cells, by increasing 
apoptosis[10,11] Endothelial injury and proliferation are fun-
damental processes leading to endothelial dysfunction, 
which plays an important part in the pathogenesis of pul-
monary vascular remodeling and hypertension, an imbal-
ance between the magnitude of injury and the capacity for 
repair.[11,12] 
A variety of experimental studies have shown that endo-
thelial progenitor cells (EPCs) contribute to the repair proc-
ess which occurs after vascular injury.[13,14] EPCs can be 
mobilized from the bone marrow into the systemic circula-
tion where they have the capacity to proliferate and differ-
entiate into mature endothelial cells of the damaged vascu-
lature. Such EPCs co-express hematopoietic stem/progeni-
tor cell markers (CD34+ or AC133+) as well as endothelial 
markers [VE-cadherin or Vascular endothelial growth factor 
receptors (VEGFR-2)].[13,14] Depletion and dysfunction of 
EPCs have been observed in patients with idiopathic PAH 
and coronary artery disease.[15−17] We therefore, in the cur-
rent study, hypothesize that in patients with decompensated 
CHF and SDB, there is increased release of OPG and deple-
tion of EPCs. Such changes may contribute to the develop-
ment of pulmonary hypertension and worsening progression 
of CHF with SDB. 
2  Methods 
2.1  Patient selection 
A total of 120 patients with decompensated CHF diag-
nosed at and admitted to Huaihe Hospital, College of Medi-
cine of Henan University were enrolled from January 1, 
2011 to December 31, 2013. All patients underwent stan-
dard care for acute CHF decompensation using intravenous 
diuretics guided by central venous pressure, and medica-
tions for chronic management derived from additional 
guidelines. The diagnosis of heart failure was made on pa-
tient history, symptomatic presentations and objective evi-
dence of systolic dysfunction defined by left ventricular 
ejection fraction (LVEF) below 45% by echocardiography. 
CHF etiology was classified as ischemic (n = 44), or idio-
pathic dilated (n = 72), on the basis of patient’s history and 
coronary angiography study with ischemic cardiomyopathy 
being defined as at least one major coronary artery (left an-
terior descending, circumflex, and right coronary) with > 
70% stenosis. All patients underwent right heart catheteriza-
tion via either the right internal jugular or right femoral vein 
approach, with PAH being defined as mean pulmonary arte-
rial pressure (mPAP) ≥ 25 mm Hg. 
All patients also underwent an overnight sleep study us-
ing a type 3 polygraph system (LS-300; Fukuda Denshi, 
Tokyo, Japan), with continuous monitoring of electrocar-
diograph (ECG), thoraco-abdominal motion, nasal airflow 
via airflow pressure transducer, and arterial oxyhemoglobin 
saturation (SpO2) via pulse oximetry. Apnea was defined as 
absence of airflow for >10 s. Hypopnea was defined as a > 
30% reduction in monitored airflow accompanied by a de-
crease in SpO2 > 4%.[18] Standard definitions were used for 
obstructive or central sleep apnea (OSA and CSA) on the 
basis of the presence or absence of rib cage and abdominal 
excursions with an absence of airflow. Respiratory Distur-
bance Index (RDI) was defined as the number of apneas and 
hypopneas per hour during sleep time in bed. Based on the 
present study and previous reports,[19,20] patients were fur-
ther classified as CHF with SDB (RDI ≥ 20 events per 
hour; Group A, n = 52), or CHF without SDB (RDI < 20 
events per hour; Group B, n = 68). 
The main exclusion criteria were age < 18 or > 90 years 
old, active pulmonary disease, primary sleep-associated 
disorders, chronic thromboembolic disease, autoimmune or 
collagen vascular disease, HIV infection, liver disease and 
unwillingness to participate, or provide blood samples. All 
participants were also free of wounds, ulcers, retinopathy, 
inflammatory or malignant disease, or recent surgery that 
may influence EPC numbers. 
2.2  Clinical characteristics and hemodynamics 
Baseline demographic data and cardiovascular risk fac-
tors were documented for all patients. These included ciga-
rette smoking status, diabetes mellitus, hypercholesterole-
mia, hypertension, atrial fibrillation. Hypertension was de-
fined as systolic/diastolic blood pressure at rest > 140/90 
mm Hg at two different clinic visits or the prescription of 
antihypertensive medication. Diabetes mellitus was defined 
as serum fasting glucose > 7.0 mmol/L or the use of hypo-
glycemic agents. Hypercholesterolemia was defined as fast-
ing total plasma cholesterol > 4.9 mmol/L. Smoking status 
was recorded as smoker (current or former) or non-smoker. 
Patients were classified as having atrial fibrillation, or no 
atrial fibrillation, on the basis of current or previous dis-
ease history and by ECG confirmation. LVEF, left ven-
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tricular end-diastolic diameter (LVEDD), right ventricular 
end-diastolic diameter (RVEDD), and left atrial diameter 
(LAD) were measured using Doppler echocardiography 
imaging. 
2.3  Isolation, culture, and characterization of circulat-
ing EPCs 
EPCs were isolated, cultured and characterized according 
to previously described techniques.[15−19] Briefly, mononu-
clear cells were isolated from the peripheral blood of pa-
tients with CHF by Ficoll density gradient centrifugation 
and cultured on fibronectin (Chemicon)-coated dishes in 
Medium 199 (Sigma) supplemented with 10% fetal-calf 
serum and VEGF (50 ng/mL, Chemicon). After four days in 
culture, adherent cells were incubated with DiLDL (Mo-
lecular Probe) and stained with FITC-labeled Ulex eu-
ropaeus agglutinin (UEA-1, Sigma). After the staining, 
samples were viewed with an inverted fluorescent micro-
scope (Leica) and further demonstrated by laser scanning 
confocal microscope (LSCM, Leica). Cells exhibiting dou-
ble-positive fluorescence were identified as differentiating 
EPCs.[18,19] Two to three independent investigators evalu-
ated the number of EPCs per well by counting 15 randomly 
selected high-power fields (×200) with an inverted fluores-
cent microscope.[17−20] 
2.4  Biochemical measurements 
Serum levels of OPG and N-terminal pro-brain natri-
uretic peptide (NT-proBNP) were quantified by ELISA with 
commercially available matched antibodies (BSD).  
2.5  Statistical analysis 
All values were expressed as mean ± SD. Student’s un-
paired t test was performed for comparison of data between 
two groups. Categorical variables were compared by means 
of the χ2 test. Correlations were tested by Pearson analysis. 
Values of P < 0.05 were considered significant. All statisti-
cal analyses were performed using SPSS 16.0. 
3  Results 
3.1  Clinical characteristics 
The clinical characteristics of the study population are 
listed in Table 1. There were no significant differences in 
age, sex gender, hypertension, diabetes, hypercholes-
terolemia, and ischemic cardiomyopathy etiology between 
the two groups (all P values > 0.05). However, the percent-
age of atrial fibrillation was significantly higher in the group 
of patients with CHF and SDB than the group without SDB 
(all P values < 0.05). 
Table 1.  Patients clinical characteristics. 
 
 
CHF – SDB 
(n = 68) 
CHF + SDB 
(n = 52) 
Age (yr) 
Men (%) 
BMI (kg/m2) 
Blood pressure (mm Hg) 
Systolic 
Diastolic 
Smoker (%) 
Diabetes mellitus (%) 
Hypercholesterolemia (%) 
Hypertension (%) 
Atrial fibrillation (%) 
Ischemic cardiomyopathy (%)
  49.80 ± 11.45 
41 (60.00) 
 24.8 ± 0.4 
 
143.5 ± 1.9 
 81.8 ± 0.8 
36 (52.94) 
12 (17.64) 
14 (20.59) 
31 (45.58) 
14 (20.58) 
26 (38.24) 
 52.45 ± 11.24 
34 (65.00) 
 27.3 ± 0.3 
 
142.9 ± 2.1 
 83.1 ± 1.0 
26 (50.00) 
10 (19.23) 
13 (25.00) 
26 (50.00) 
23 (44.20)* 
18 (34.61) 
Data are expressed as mean ± SD or as n (%). *P < 0.05 for atrial fibrillation. 
BMI: body mass index; CHF: congestive heart failure; SDB: sleep-disorder-
ed breathing. 
3.2  Doppler echocardiography imaging parameters 
and mean pulmonary artery pressures 
As listed in Table 2, Doppler echocardiography imaging 
showed that CHF patients with SDB had no significant dif-
ferences in the LVEDD comparing with those without SDB 
(all P values > 0.05). However, the LAD and RVEDD were 
significantly larger in the SDB group (all P values < 0.05). 
Mean pulmonary artery blood pressures obtained by right 
heart catheterization were also significantly higher in CHF 
patients with SDB than CHF without SDB (all P values < 
0.05), and the LVEF was significantly lower in the SDB 
group (P values < 0.05). 
3.3  Circulating levels of OPG, NT-proBNP, and EPCs 
The levels of serum OPG and NT-proBNP from CHF 
patients with and without SDB are shown in Table 3. Sig-
nificant differences exist between the two groups (all P val-
ues < 0.05). The numbers of EPCs were expanded from  
Table 2.  Echocardiographic parameters in patients with or 
without SDB. 
 CHF – SDB (n = 68) CHF + SDB (n = 52)
LVEDD (mm) 
LVEF (%) 
LAD (mm) 
RVEDD (mm) 
mPAP (mm Hg) 
67.90 ± 13.20 
42.40 ± 12.80 
42.20 ± 7.10 
21.80 ± 4.40 
36.40 ± 4.10 
69.20 ± 9.60 
31.60 ± 11.40* 
50.20 ± 9.30* 
28.30 ± 7.00* 
50.20 ± 9.50* 
*P < 0.05. Data are expressed as mean ± SD. CHF: congestive heart failure; 
LAD: left atrial diameter; LVEDD: left ventricular end diastolic diameter; 
LVEF: left ventricular ejection fraction; mPAP: mean pulmonary arterial 
pressure; RVEDD: right ventricular end diastolic diameter; SDB: sleep-dis-
ordered breathing. 
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Table 3.  Circulating levels of OPG, NT-proBNP and EPC 
numbers in patients with or without SDB. 
 
 
CHF - SDB 
(n = 68) 
CHF + SDB 
(n = 52) 
OPG (pg/mL) 
NT-proBNP (ng/mL) 
EPCs (number) 
551.29 ± 42.12 
3028.60 ± 811.90 
45.17 ± 10.51 
789.83 ± 89.38* 
5946.50 ± 1434.50* 
29.30 ± 9.01 * 
* P < 0.05. Data are expressed as mean ± SD. CHF: congestive heart failure; 
EPC: endothelial progenitor cell; NT-proBNP: N-terminal pro-brain natri-
uretic peptide; OPG: osteoprotegerin; SDB: sleep-disordered breathing. 
 
human blood in vitro and identified by DiLDL uptake and 
lectin staining as shown in Figure 1 (panels A1 to B3). EPC 
numbers decreased significantly in subjects with SDB pa-
tients compared with those without SDB (29.30 ± 9.01 vs. 
45.17 ± 10.51 EPCs/ × 200 field; P < 0.05). Both OPG 
(789.83 ± 89.38 vs. 551.29 ± 42.12 pg/mL; P < 0.05) and 
NT-proBNP (5946.50 ± 1434.50 vs. 3028.60 ± 811.90 
ng/mL; P < 0.05) were also significantly elevated in CHF 
patients with SDB. EPC numbers correlated inversely with 
RDI (r = –0.45, P = 0.037) and blood level of OPG (r = 
–0.53, P = 0.011). Blood levels of NT-proBNP were also 
increased significantly in patients with decompensated CHF 
and SDB, but had no significant correlation with either 
EPCs or RDI. 
 
Figure 1.  Characteristics of CHF patient’s with or without SDB peripheral blood mononuclear cells after seven days of culture. 
Adherent cells lectin binding (green, exciting wave-length 477 nm) and DiLDL uptake (red, exciting wave-length 543 nm) were assessed 
under a laser scanning confocal microscope. Double positive cells appearing yellow in the overlay were identified as differentiating EPCs (× 
200). Panels A1-A3: CHF with SDB. Panels B1-B3: CHF without PAH. CHF: congestive heart failure; EPCs: endothelial progenitor cells; 
PAH: pulmonary arterial hypertension; SDB: sleep-disordered breathing. 
4  Discussion 
The current study demonstrates that patients of decom-
pensated heart failure with SDB have significantly de-
creased circulating EPCs and increased level of OPG from 
peripheral blood. These SDB patients also have significantly 
elevated mPAP. There is an inverse relationship between 
the changes in EPCs and OPG. SDB is known to cause hy-
poxemia. This likely contributes to the elevation in circulat-
ing OPG which in turn may cause depletion of EPCs and 
damage to the pulmonary vascular endothelial function re-
sulting in adverse remodeling and development of pulmo-
nary hypertension.  
Heart failure is well recognized as a major cause of mor-
tality and morbidity. The progressive nature of CHF symp-
toms lead to chronic disability and impaired quality of life. 
SDB is known to occur frequently in patients with CHF and 
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may be a predictor of poor prognosis.[3,4] In a study by 
Macdonald, et al.[21] SDB was found in 55% of patients with 
asymptomatic heart failure with LVEF less than 40%. An-
other study by Tremel, et al.[20] found 82% of the patients 
with heart failure also had SDB.In our study, 43% of pa-
tients with moderately depressed left ventricular systolic 
function were found to have SDB during index hospitaliza-
tion. However, we also demonstrated that these patients had 
significantly elevated mPAP. This evidence lends to support 
the premise that hypoxemia may contribute to the pulmo-
nary vascular endothelial dysfunction, remodeling, and de-
velopment of pulmonary hypertension in heart failure pa-
tients with SDB. Although the detailed mechanisms are yet 
to be determined, SDB with resultant hypoxemia causing 
oxidative stress and pulmonary vasculature endothelial 
dysfunction remains elusive.  
Also, well recognized is the development of pulmonary 
hypertension during progression in the majority of patients 
with chronic heart failure, which in turn results in worsening 
prognosis and complicating effective treatment.[11,22] Ex-
perimental studies over the past decades have led to rapid 
advancement in the mechanisms of PAH during heart fail-
ure, which is now thought not to be solely due to a “pas-
sive” increase in pulmonary vascular pressures from ele-
vated end diastolic pressure of the left ventricle, but rather a 
“reactive” contribution from the pulmonary vascular endo-
thelial dysfunction and vascular remodeling.[1,2,22] This en-
dothelial dysfunction ultimately represents an imbalance 
between the magnitude of vascular injury and its capacity 
for repair. There is strong evidence that circulating EPCs 
may play an important role in endothelium maintenance, 
being implicated in both re-endothelialization and 
neo-vascularization.[12,22] Clinical studies have demonstrated 
that the number of circulating EPCs has an inverse relation-
ship to the Framingham risk score and vascular endothelial 
function in healthy subjects.[22,23] There is a decreased num-
ber of circulating EPCs in coronary artery disease patients 
who smoke.[16] In addition, experimental animals transplan-
tation of EPCs has modestly attenuated monocrotaline-in-
duced pulmonary hypertension (16% decrease in pulmonary 
vascular resistance). Intravenous infusion of autologous 
EPCs has beneficial effects on exercise capacity and pul-
monary hemodynamics in adults with idiopathic PAH.[15] In 
this regard, our study demonstrated that circulating EPCs 
were significantly depleted in patients of systolic heart fail-
ure with SDB. This might suggest that the role of depletion 
of EPCs contributes to endothelial dysfunction and develop-
ment of pulmonary hypertension in patients with SDB, 
which lead to worsening heart failure.[7,8,24] Therefore, sup-
plementation of EPCs might reverse this disease process 
and improve outcome. 
OPG is a soluble member of the tumor necrosis factor 
(TNF) receptor family. Numerous reports confirm the in-
volvement of TNF-α in the pathogenesis of heart fail-
ure.[25,26] Traditionally, OPG binds to the receptor activator 
of NF-κB ligand (RANKL) and competitively inhibits the 
interaction between RANKL and RANK, thus regulating 
osteoclast differentiation.[10,11,27] Recent experimental, clini-
cal, and epidemiological data have also implicated a sig-
nificant role of this signaling axis in the development and 
progression of cardiovascular diseases, such as aortic valve 
calcification, atherosclerosis, and diabetic macroangiopa-
thy.[28−31] In both experimental animal models and clinical 
heart failure patients, elevated myocardial protein expres-
sion of OPG and dysregulated RANKL/OPG signaling axis 
have been demonstrated. These findings may suggest an 
important role of this axis in ventricular and vascular re-
modeling, which may lead to worsening myocardial func-
tion and clinical prognosis.[32−34] 
A variety of pathological conditions are associated with 
elevations of circulating OPG.[34,35] In experimental animals 
reduced BMPR2 expression stimulates OPG expression and 
secretion from pulmonary artery smooth muscle cells.[35,36] 
Interestingly, elevated levels of OPG have also been ob-
served in PAH associated with congenital heart disease.[37,38]  
In our study circulating OPG is significantly increased in 
peripheral blood from patients with heart failure decom-
pensated SDB compared to those patients without SDB. Our 
finding of a negative correlation between the OPG level and 
the number of EPCs supports the hypothesis that elevated 
OPG may down regulate circulating EPCs causing dysfunc-
tion of the endothelium, which plays an important part in 
the pathogenesis of pulmonary vascular remodeling and 
development of pulmonary hypertension in patients with 
SDB. Although the concentration of NT-proBNP, a well- 
established heart failure marker, was also increased signifi-
cantly in peripheral blood from heart failure patients with 
SDB, the blood level of NT-proBNP had no correlation with 
circulating EPCs and RDI.[39–41] This is consistent with pre-
vious studies showing that although the NT-proBNP level 
correlated with the severity of heart failure symptoms, it had 
no correlation with pulmonary vascular remodeling.[39] Ko-
yama, et al.[42] have investigated the potential benefit of an 
therapy such as short term use of adaptive servo ventilation 
in CHF measuring CHF parameters in 17 patients before 
and after nocturnal ventilation therapy using adaptive servo 
ventilation. They demonstrated an improvement during 
therapy for the following parameters: level of NT-proBNP, 
ejection fraction, and NYHA-class. The conclusion sug-
gested adaptive servo ventilation therapy to be important 
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contributors for decreasing NT-proBNP and improving car-
diac function in patients with CHF accompanied by SDB.[42] 
However, whether this adequate treatment can decrease 
pulmonary artery pressure is still unknown. 
This study has several limitations: first, the relatively 
small study population and a rather selected disease stage 
(i.e., systolic heart failure with at least moderately depressed 
left ventricular systolic function during decompensation) 
limit any possible generalization of our finding. However, 
effective intervention at this disease stage may render the 
most rewarding outcome including reversal of disease pro-
gression. Second, the direct functional study of circulating 
EPCs was not performed. Thus, the contribution of depleted 
EPCs to the development of pulmonary hypertension re-
mains speculative. Thirdly, the molecular pathway of OPG 
responsible for impairment in circulating EPCs is yet to be 
determined, especially in this type of human study. 
In conclusion, CHF patients with SDB had increased 
circulating OPG, depleted EPCs, and elevated mPAP. The 
inverse relationship of circulating OPG with EPCs suggests 
a likely mechanism for SDB and hypoxemia to stimulate 
OPG in the development of pulmonary vascular dysfunction, 
thus worsening prognosis for chronic CHF. 
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